1p/19q codeletion induces targetable and imageable vulnerabilities in glucose metabolism in oligodendrogliomas

Area of Science:

• Oncology
• Metabolic Engineering
• Molecular Biology

Background:

• The 1p/19q co-deletion is a defining genetic alteration in oligodendrogliomas.
• Understanding the metabolic consequences of this co-deletion is crucial for developing targeted therapies.

Purpose of the Study:

• To identify and exploit metabolic vulnerabilities associated with the 1p/19q co-deletion in oligodendrogliomas.
• To evaluate novel therapeutic strategies and non-invasive imaging techniques for oligodendroglioma treatment.

Main Methods:

• Utilized stable isotope tracing ([U-13C]-glucose) and mass spectrometry in patient-derived oligodendroglioma models.
• Employed genetic and pharmacological approaches to investigate metabolic pathways.
• Assessed deuterium metabolic imaging (DMI) with [6,6'-2H]-glucose for early treatment response monitoring.

Main Results:

• Downregulation of enolase 1 (ENO1) and upregulation of enolase 2 (ENO2) were observed due to the 1p/19q co-deletion and epigenetic modifications.
• Inhibition of ENO2 or phosphoglycerate dehydrogenase (PHGDH) individually showed anti-proliferative effects.
• Combined inhibition of ENO2 and PHGDH (synthetic lethality) led to tumor regression in vivo.
• DMI of lactate production from [6,6'-2H]-glucose provided an early, non-invasive readout of therapeutic response.

Conclusions:

• ENO2 and PHGDH represent key metabolic vulnerabilities in 1p/19q co-deleted oligodendrogliomas.
• Combination therapy targeting ENO2 and PHGDH demonstrates significant therapeutic potential.
• [6,6'-2H]-glucose DMI serves as a promising non-invasive biomarker for early treatment response assessment.